Celcuity (CELC) Competitors $13.79 +0.75 (+5.75%) Closing price 07/3/2025 03:07 PM EasternExtended Trading$13.79 0.00 (0.00%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. PGNY, GRAL, NHC, TDOC, AHCO, VRDN, CDNA, PNTG, AVAH, and AGLShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), AdaptHealth (AHCO), Viridian Therapeutics (VRDN), CareDx (CDNA), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), and Agilon Health (AGL). These companies are all part of the "healthcare" industry. Celcuity vs. Its Competitors Progyny GRAIL National HealthCare Teladoc Health AdaptHealth Viridian Therapeutics CareDx The Pennant Group Aveanna Healthcare Agilon Health Celcuity (NASDAQ:CELC) and Progyny (NASDAQ:PGNY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of CELC or PGNY? 63.3% of Celcuity shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 15.8% of Celcuity shares are held by insiders. Comparatively, 9.4% of Progyny shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CELC or PGNY? In the previous week, Celcuity had 4 more articles in the media than Progyny. MarketBeat recorded 9 mentions for Celcuity and 5 mentions for Progyny. Progyny's average media sentiment score of 0.29 beat Celcuity's score of 0.24 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, CELC or PGNY? Celcuity has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Is CELC or PGNY more profitable? Progyny has a net margin of 4.33% compared to Celcuity's net margin of 0.00%. Progyny's return on equity of 10.90% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets CelcuityN/A -96.21% -49.44% Progyny 4.33%10.90%7.20% Which has stronger earnings and valuation, CELC or PGNY? Progyny has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelcuityN/AN/A-$111.78M-$3.03-4.55Progyny$1.17B1.58$54.34M$0.5737.63 Do analysts rate CELC or PGNY? Celcuity currently has a consensus target price of $28.40, suggesting a potential upside of 105.95%. Progyny has a consensus target price of $23.45, suggesting a potential upside of 9.35%. Given Celcuity's stronger consensus rating and higher probable upside, research analysts plainly believe Celcuity is more favorable than Progyny.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Progyny 0 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.42 SummaryProgyny beats Celcuity on 10 of the 15 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$522.23M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-4.5521.5627.6020.30Price / SalesN/A172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book4.437.518.055.68Net Income-$111.78M-$55.05M$3.18B$249.13M7 Day Performance9.97%4.61%2.82%3.30%1 Month Performance15.11%4.89%3.70%5.20%1 Year Performance-15.45%5.84%35.41%21.38% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity2.1709 of 5 stars$13.79+5.8%$28.40+105.9%-15.5%$522.23MN/A-4.5540Analyst ForecastPGNYProgyny1.1012 of 5 stars$22.00+0.4%$23.45+6.6%-24.1%$1.88B$1.17B38.60310GRALGRAIL0.7001 of 5 stars$51.42+6.3%$31.50-38.7%N/A$1.74B$125.60M-0.841,360Insider TradeGap DownNHCNational HealthCareN/A$107.01-1.0%N/A-2.7%$1.65B$1.37B13.4112,400TDOCTeladoc Health3.21 of 5 stars$8.73+3.8%$9.60+9.9%-11.0%$1.48B$2.57B-1.475,500AHCOAdaptHealth4.0514 of 5 stars$9.43-1.3%$13.40+42.1%-7.4%$1.29B$3.26B16.5410,500News CoverageVRDNViridian Therapeutics1.8247 of 5 stars$13.98-2.4%$37.56+168.6%+27.2%$1.17B$300K-3.6350News CoverageCDNACareDx4.3656 of 5 stars$19.54+1.6%$30.33+55.2%+28.9%$1.07B$333.79M16.99740PNTGThe Pennant Group3.7063 of 5 stars$29.85+0.2%$34.60+15.9%+8.1%$1.03B$695.24M39.287,000High Trading VolumeAVAHAveanna Healthcare1.1847 of 5 stars$5.23+4.2%$5.13-2.0%+74.5%$979.37M$2.02B261.5033,500Analyst ForecastHigh Trading VolumeAGLAgilon Health2.2991 of 5 stars$2.31flat$4.79+107.2%-60.0%$956.23M$6.06B-3.921,076 Related Companies and Tools Related Companies Progyny Competitors GRAIL Competitors National HealthCare Competitors Teladoc Health Competitors AdaptHealth Competitors Viridian Therapeutics Competitors CareDx Competitors The Pennant Group Competitors Aveanna Healthcare Competitors Agilon Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
